Geron Corporation (GERN) Stock Analysis

Geron Corporation (GERN) is a publicly traded company in the HEALTHCARE sector. It trades at $1.17, carries a market capitalization of $776.24M. This page summarizes the public market data, fundamentals, and frequently asked questions for GERN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.17
• Market Cap: $776.24M
• EPS: $-0.11
• 52-Week High: $2.01
• 52-Week Low: $1.04

Market Sentiment

Geron Corporation currently has a Neutral sentiment score of 0.10.

About Geron Corporation

Geron Corporation is a clinical biopharmaceutical company headquartered in Foster City, California, specializing in the development and commercialization of innovative therapies for myeloid hematologic neoplasms, particularly acalabrutinib and telomerase inhibitors. With a robust pipeline and a commitment to addressing unmet medical needs in this field, Geron aims to transform the treatment landscape for patients with blood cancers. The company is positioned at the forefront of hematology res...

GNG Research Analysis

GNG Research scores Geron Corporation (GERN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GERN.

Frequently Asked Questions

Does GERN pay dividends?

Geron Corporation (GERN) does not currently pay a regular dividend.

What is GERN's market cap?

Geron Corporation (GERN) has a market capitalization of $776.24M with a current stock price of $1.17.